Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study investigated the integration of crystal engineering and microneedle technology for androgenetic alopecia treatment, finding that microneedles loaded with newly developed Kopexil multicomponent crystals reduced drug diffusion rates in vitro compared to standard formulations.

Bexarotene gel shows promise as a new treatment for alopecia areata.

This study details a case of a 20-year-old woman with APECED syndrome and alopecia areata who experienced complete scalp hair regrowth and improved quality of life after nine months of ruxolitinib treatment, highlighting the drug's effectiveness for severe AA linked to AIRE gene mutation.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

The trial is ongoing, but researchers are evaluating the efficacy and safety of REZPEG, a potential new therapy for severe alopecia areata, which selectively expands regulatory T cells.

This study presents case reports of four patients with alopecia areata or alopecia universalis, highlighting varied responses to treatments like prednisone, intralesional triamcinolone, and squaric acid dibutyl ester.

Clofazimine may be effective for treating ashy dermatosis.

This study found that hydro-alcoholic Eclipta alba extract may have anticancer and multidrug resistance-reversal effects in animal models, suggesting potential as an adjunctive agent in tumor chemotherapy.

This study found increased Zyxin expression in affected hair follicles of androgenetic alopecia patients and suggested its potential role in the condition's pathogenesis and as a therapeutic target.

The trial helped find the best dose of deuruxolitinib for treating alopecia areata.

In this study, topical 5% roxithromycin was effective in restoring hair growth in about half of individuals with androgenetic alopecia without causing adverse effects.

This study suggests that the neurosteroid allopregnanolone contributes to stress resistance in mice, and the ALLO mimetic drug alfaxalone may offer anxiolytic benefits without muscle-relaxant effects.

Cromolyn sodium's effectiveness for treating asthma in children under 2 is unclear, possibly more beneficial for older children, and further research is needed.

This study found that adding fexofenadine to DPCP treatment in non-atopic Alopecia areata patients did not significantly improve hair regrowth, but it did significantly reduce treatment-related discomfort.

In this study, a novel compound named AH-001 demonstrated effective androgen receptor protein degradation, reducing hair loss progression in a mouse model of androgenetic alopecia, with minimal systemic exposure and side effects, suggesting potential for safer treatment.

This study explored the solubility and crystal structure of GI197111X, a 5-alpha reductase inhibitor for androgenetic alopecia, finding its solubility in Capmul MCM suitable for a soft gel dosage form.

This meta-analysis found that deuruxolitinib significantly improved hair regrowth and patient satisfaction in those with moderate to severe alopecia areata compared to placebo, though it was associated with manageable side effects such as elevated creatinine kinase levels, headaches, and acne, especially at higher doses.

Bexarotene 1% topical gel helped some patients with alopecia areata regrow hair.

In this study, a genetic analysis identified a pathogenic variant in the ALOXE3 gene associated with non-bullous congenital ichthyosiform erythroderma, and the patient's response to antifungal treatment highlights the risk of cutaneous fungal infections.

In this study, Caizhixuan hair tonic was found to promote hair growth in androgenetic alopecia mice by regulating the PI3K/Akt and apoptosis pathways.

In this study, analysis of FDA data revealed a substantial risk of dermatologic adverse events with aromatase inhibitors, especially anastrozole and exemestane, highlighting the importance of dermatologic monitoring during such therapies.

This article reviews the development milestones of clascoterone up to its first approval for treating acne vulgaris, reporting no new clinical results for androgenetic alopecia.

This study found that topical phenylephrine, an α1-AR agonist, significantly reduced hair shedding and increased epilation force threshold in women experiencing traction alopecia during cosmetic procedures.

This study developed and validated a sensitive and rapid method to simultaneously measure alfuzosin and dutasteride in human plasma, enabling high-throughput analysis for pharmacokinetic and bioequivalence studies.

This study found that azelaic acid entrapped in transethosomes exhibited enhanced antidermatophyte activity and improved treatment outcomes in guinea pig models of dermatophytosis compared to free azelaic acid.

This study found that oral tofacitinib was effective and well tolerated for treating alopecia areata in most pediatric patients, with nearly 73% experiencing hair regrowth.

This article reviews the potential of Acyzol, a zinc-containing drug, to treat and prevent zinc deficiency conditions, but it reports no new clinical findings.